TD Cowen upgraded Genmab to Buy with a new $43 price target, signaling confidence in upside potential beyond its previous $32 target. Genmab’s diversified product base — including Darzalex royalties, EPKINLY, Tivdak, and the Merus transaction — underpins the bull case, complemented by a generally positive broker landscape and ongoing milestones with AbbVie- partnered lymphoma therapies in Europe and Japan. In Q1 2026 Genmab reported revenue of €736 million, net income of €287 million, and diluted EPS of €4.29, with operating profit of €338 million and a robust margin of around 45.9% of revenue, highlighting improving profitability alongside growth. The company also posted a strong balance sheet with €3.0 billion in cash and equivalents and €5.4 billion in equity, supporting pipeline spending and business development as costs rose with higher revenue. Analysts view near-term catalysts as pivotal, stressing that execution risk and the balance between today’s cash flows and tomorrow’s pipeline continue to frame investor sentiment. Overall market chatter shows a bullish sentiment with multiple firms initiating or lifting ratings and price targets, echoing TD Cowen’s upbeat view of Genmab’s potential.